ASM
DMAA

ATW SPAC Management’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

ATW SPAC Management’s Portfolio DMAA Stock Details DMAA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$5.13M Sell
500,000
-70,000
-12% -$718K 6.48% 3
2025
Q2 		$5.81M Hold
570,000
– – 8.9% 3
2025
Q1 		$5.71M Buy
+570,000
New +$5.7M 9.53% 3

Other funds holding DMAA

KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

ATW SPAC Management's DMAA Position: Q3 2025 in Review

ATW SPAC Management reduced its Drugs Made In America Acquisition Corp (DMAA) stake by 12% in Q3 2025, selling an estimated $718K and leaving 500,000 shares worth $5.13M. The position accounts for 6.48% of the portfolio, ranked #3.

ATW SPAC Management first reported a position in DMAA in Q1 2025 and has held it in 3 quarters since. The position peaked at $5.81M in Q2 2025. 37 funds tracked by Wall St. Rank hold DMAA as of Q3 2025.

  • ATW SPAC Management held 500,000 shares of Drugs Made In America Acquisition Corp worth $5.13M as of Q3 2025.
  • ATW SPAC Management sold 70,000 Drugs Made In America Acquisition Corp shares in Q3 2025, an estimated $718K.
  • Drugs Made In America Acquisition Corp made up 6.48% of ATW SPAC Management's portfolio in Q3 2025, its #3 holding.
  • ATW SPAC Management first reported a position in Drugs Made In America Acquisition Corp in Q1 2025 and has held it in 3 quarters since.
  • ATW SPAC Management's Drugs Made In America Acquisition Corp position peaked at $5.81M in Q2 2025.
  • 37 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q3 2025.

Based on ATW SPAC Management's 13F filing for Q3 2025, filed 12 Nov 2025.